MedBioSphere
Articles Videos The Web  
    

AstraZeneca Receives FDA Approval

Selected Abstract

AstraZeneca Receives FDA Approval for ENTOCORT(TM) EC (budesonide) Capsules For Crohn's Disease.
ENTOCORT EC Offers Patients With Mild to Moderate Disease An Effective and Well-Tolerated New Treatment WILMINGTON, Del., Oct. 3 /PRNewswire/ -- AstraZeneca announced today that it received U.S. Food and Drug Administration (FDA) approval to market ENTOCORT(TM) EC (budesonide) capsules for the ...
October 3, 2001; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. Merck 2Q Profit More than Doubles and AstraZeneca Receives FDA Approval for Asthma Drug.
2. AstraZeneca receives FDA approval for new cancer drug IRESSA (gefitinib, ZD1839).
3. AstraZeneca Receives FDA Approval to Market Atacand HCT(TM); Combination Product Offers Patients New Advance in Controlling Blood Pressure.
4. AstraZeneca Receives FDA Approval for ENTOCORT(TM) EC (budesonide) Capsules For Crohn's Disease.
5. gefitinib, ZD1839); IRESSA is the First in a New Class of Drugs for the Treatment of Advanced Non-Small Cell Lung Cancer-Only FDA-Approved Option for Third Line Patients.
6. AstraZeneca Receives FDA Approval for New Cancer Drug IRESSA(R) (gefitinib); IRESSA Is the First In New Class of Drugs for the Treatment of Advanced Non-Small Cell Lung Cancer-Only FDA Approved Option for Third Line Patients.
7. PR Newswire National Summary, Monday, May 5, noon to 2 p.m. ET.